TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Adagene Inc.
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.

Insights
EURKU   positive

Successfully identifying and merging with an innovative technology company in the marine sector


ADAG   positive

Secured a strategic licensing agreement with potential significant financial upside and expanded technology application